Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.
Guests Ryan Abbott, a professor of law and medicine, as well as the leader of the Artificial Inventor Project, and Jim Belfiore, senior vice president of innovation at Clarivate plc, have a discussion about the brave new world AI is creating.
Insights into the controversial drug come from guests Michael Agadjanyan, president of Nuravax Inc., which is developing antibodies for preventing Alzheimer’s and Parkinson’s diseases, along with Robert Glanzman, chief medical officer of Clene Nanomedicine Inc.
A conversation with Kleanthis Xanthopoulos, a co-founder and executive chairman of Shoreline Biosciences, and Joe Hernandez, CEO and executive chairman of Blue Water Vaccines, who have founded or led eight health care and pharmaceuticals companies.
Paul Testa, executive vice president for operations and supply chain at Tokyo-based Kyowa Kirin, on the dramatic importance of continuity, reliability of supply, business process and automation.
Peter Pitts, president of the Center for Medicine in the Public Interest, on how government regulation seems like a slow but in actuality moves more quickly than understood.